IFNA1 and systemic lupus erythematosus: In summary, our findings underscore that both IFN-dependent and IFN-independent pathways contribute to clinical heterogeneity in SLE and that anti-IFN-I therapies are more likely to be beneficial in patients with high levels of bioactive IFN-I rather than a high IFN signature.